Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):3. https://doi.org/10.3390/medsci9010003.
Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31:1915–21. https://doi.org/10.1038/leu.2016.380.
Article CAS PubMed PubMed Central Google Scholar
Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–8. https://doi.org/10.1038/leu.2017.138.
Article CAS PubMed Google Scholar
Minařík J, Ševčíková S. Immunomodulatory agents for multiple myeloma. Cancers (Basel). 2022;14(23):5759. https://doi.org/10.3390/cancers14235759.
Article PubMed PubMed Central Google Scholar
Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs History of immunomodulatory drugs (IMiDs). Int J Hematol. 2016;104:293–9. https://doi.org/10.1007/s12185-016-2073-4.
Article CAS PubMed Google Scholar
Hideshima T, Raje N, Richardson PG, Anderson KC. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag. 2008;4(1):129–36. https://doi.org/10.2147/tcrm.s1445.
Article CAS PubMed PubMed Central Google Scholar
Martinez-Høyer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020;91:22–31. https://doi.org/10.1016/j.exphem.2020.09.196.
Article CAS PubMed Google Scholar
Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9(2):19. https://doi.org/10.1038/s41408-019-0173-0.
Article PubMed PubMed Central Google Scholar
Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 2013;1(1):5. https://doi.org/10.1186/2050-7771-1-5.
Article PubMed PubMed Central Google Scholar
Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai Y-T, et al. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020;136(20):2334–45. https://doi.org/10.1182/blood.2019004332.
Article PubMed PubMed Central Google Scholar
Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23:10–24. https://doi.org/10.1038/leu.2008.259.
Article CAS PubMed Google Scholar
Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia. 2010;12:28–38. https://doi.org/10.1593/neo.91192.
Article CAS PubMed PubMed Central Google Scholar
Sanchez E, Li M, Patil S, Soof CM, Nosrati JD, Schlossberg RE, et al. The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo. Ann Hematol. 2019;98:691–703. https://doi.org/10.1007/s00277-019-03595-0.
Article CAS PubMed Google Scholar
Gupta N, Mayer D. Interaction of JAK with steroid receptor function. JAKSTAT. 2013;2: e24911. https://doi.org/10.4161/jkst.24911.
Article PubMed PubMed Central Google Scholar
Monaghan KA, Khong T, Burns CJ, Spencer A. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia. 2011;25:1891–9. https://doi.org/10.1038/leu.2011.175.
Article CAS PubMed Google Scholar
Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, et al. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD451 myeloma cells. Am J Hematol. 2010;85:675–86. https://doi.org/10.1002/ajh.21785.
Article CAS PubMed PubMed Central Google Scholar
Xu N, Yu E, Ng N, Li M, Bujarski S, Hekmati A, et al. The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma. Hematol Oncol. 2023;41:578–82. https://doi.org/10.1002/hon.3071.
Article CAS PubMed Google Scholar
Chen H, Sanchez E, Li M, Wang C, Gillespie A, Shvartsur A, et al. Anti-myeloma activity by the combination of the JAK2 inhibitor ruxolitinib with lenalidomide and corticosteroids. Blood. 2014;124(21):2114. https://doi.org/10.1182/blood.V124.21.2114.2114.
Chen H, Li M, Ng N, Yu E, Bujarski S, Yin Z, et al. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. Br J Haematol. 2020;192:568–76. https://doi.org/10.1111/bjh.17282.
Article CAS PubMed Google Scholar
Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Ng N, et al. JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression. Br J Haematol. 2020;188:283–94. https://doi.org/10.1111/bjh.16158.
Article CAS PubMed Google Scholar
Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015;75:297–308. https://doi.org/10.1007/s40265-015-0351-8.
Article CAS PubMed Google Scholar
Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35. https://doi.org/10.1056/nejmoa1409002.
Article PubMed PubMed Central Google Scholar
De Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson FG, De Carvalho MF, et al. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: a rationale for JAK/STAT pathway inhibition in myeloma patients. Cancer Lett. 2017;403:206–15. https://doi.org/10.1016/j.canlet.2017.06.016.
Article CAS PubMed Google Scholar
Krasil’nikov M, Shatskaya V. Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. J Steroid Biochem Mol Biol. 2002;82:369–76.
Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51:1644–54. https://doi.org/10.1177/0091270010389469.
Article CAS PubMed Google Scholar
Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712–20.
Article CAS PubMed Google Scholar
Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K-L, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-KB. Blood. 1996;87(3):1104–12.
Article CAS PubMed Google Scholar
Maïga S, Gomez-Bougie P, Bonnaud S, Gratas C, Moreau P, Le Gouill S, et al. Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma. Br J Cancer. 2013;108:1801–6. https://doi.org/10.1038/bjc.2013.186.
Article CAS PubMed PubMed Central Google Scholar
Berenson JR, Kim C, Bujarski S, To J, Spektor TM, Martinez D, et al. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematol Oncol. 2022;40:906–13. https://doi.org/10.1002/hon.3066.
Article CAS PubMed Google Scholar
Berenson JR, To J, Spektor TM, Martinez D, Turner C, Sanchez A, et al. A phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed/refractory multiple myeloma. Clin Cancer Res. 2020;26:2346–53. https://doi.org/10.1158/1078-0432.CCR-19-1899.
Article CAS PubMed Google Scholar
Berenson JR, Martinez D, Safiae T, Boccia R, Yang H, Moezi M, et al. Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma. Br J Haematol. 2022;200:722–30.
Loscocco GG, Vannucchi AM. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. Int J Hematol. 2022;115(5):626–44. https://doi.org/10.1007/S12185-022-03335-7.
Article CAS PubMed Google Scholar
Hu X, li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https://doi.org/10.1038/s41392-021-00791-1.
留言 (0)